Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8595943 | 0.84 | KMT2A (0.59) | KMT2AMEN1POLBPLGPLAT | |
| SCHEMBL8595946 | 0.84 | KMT2A (0.59) | KMT2AMEN1POLBPLGPLAT | |
| SCHEMBL3335282 | 0.83 | EPHX1 (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL8596277 | 0.78 | KMT2A (0.57) | KMT2AMEN1POLBPLGPLAT | |
| SCHEMBL8597460 | 0.76 | KMT2A (0.54) | KMT2AMEN1POLBPLGPLAT | |
| SCHEMBL8598968 | 0.75 | KMT2A (0.53) | KMT2AMEN1POLBPLGPLAT | |
| SCHEMBL8599100 | 0.73 | KMT2A (0.52) | KMT2AMEN1POLBPLGPLAT | |
| SCHEMBL8601004 | 0.73 | KMT2A (0.52) | KMT2AMEN1POLBPLGPLAT | |
| SCHEMBL1107035 | 0.73 | TDP1 (0.52) | KMT2AMEN1SMN1; SMN2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL8596530 | 0.72 | KMT2A (0.51) | KMT2AMEN1POLBPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145057-A1 | NOVEL PRODRUGS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2010-06-10 | — | — | US | claimed |
| EP-2118052-A2 | NOVEL PRODRUGS | Sun Pharma Advanced Research Company Ltd (IN) | 2009-11-18 | — | — | EP | claimed |
| WO-2008111096-A2 | NOVEL PRODRUGS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2008-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145057-A1 | NOVEL PRODRUGS | UGT2B7, UGT1A1, UGT1A6 | KMT2A 2650/4885MEN1 1633/4885POLB 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.